These three innovators to know are responsible for solving problems here in Houston. Courtesy photos

A good innovator sees a need and fills it. Whether it's a bigger budget for new hospital technology, a network for female software developers in Houston, or access to creatives for nonprofits, these three Houston innovators are responsible for filling the needs of Houston's innovation ecosystem.

Roberta Schwartz, chief innovation officer of Houston Methodist

Roberta Schwartz is leading the innovation initiative at Houston Methodist. Courtesy of Houston Methodist

Houston Methodist has always been an innovative hospital system, says Roberta Schwartz, chief innovation officer, so it was not really that surprising that a group of hospital officials had an interest in new technologies.

"As we watched these technologies come in, we found that there were a number of us within the organization that were just talking about it all the time and watching how we could really revolutionize the way we worked by embracing these new technologies," Schwartz says.

The group named itself the "digital innovation obsessed people," however, now that group calls itself the Houston Methodist Center for Innovation, and Schwartz is leading the initiative. Read more about Schwartz and the new center here.

Alex Anderson, founder of Good Measure

Alex Anderson started Good Measure to help nonprofits have access to creatives and storytelling tools. Courtesy of Alex Anderson

Houston-based nonprofit, Good Measure, completed its third creative workshop last week — and its first outside of Houston. Nuu Group's Alex Anderson and Tres Garner founded Good Measure to help nonprofits with storytelling and media, and they took their efforts to New York City to work with Memphis-based youth violence nonprofit, Grounded.

Just like the last Good Measure project, volunteer creatives has less than 72 hours to create a slew of branding materials, including user experience-focused designs, web pages, photos, videos, and more for the nonprofit.

"My hope is that each and every individual who attended sees the impact that our craft skills can make," Anderson wrote in a post on Medium. "We certainly can volunteer our time and work with nonprofits, but the real question is whether we can return to our day jobs, to clients with big budgets and capitalistic mindsets, and influence their decisions—to push them from opportunistic to purposeful."

Silver Ehiwario, director of Women Who Code Houston Chapter

Silver Ehiwario flipped careers a while back, and now she hopes to help other women with that process. Courtesy of Silver Ehiwario

Making a career switch is never easy — but it's extremely hard for women trying to enter the technology industry. Women Who Code, a global organization, just opened up shop in Houston, thanks to seven female directors, including Silver Ehiwario, who changed her career to tech recently.

"We are able to see a lot of people are changing their careers from what they have done before — just like I changed mine," she says. "We need communities where they can be inspired." Read more about Ehiwario and Women Who Code here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”